Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.VGX Pharmaceuticals has submitted two separate investigational new drug applications to the FDA for Phase I clinical studies of VGX-3100 and VGX-3400 vaccines. Both the candidate vaccines have been developed using VGX's integrated DNA vaccines and therapies platform and are based on its SynCon vaccine technology.
Subscribe to our email newsletter
VGX-3100 is a DNA-based therapeutic vaccine that has the potential to treat cervical cancer caused by the human papilloma virus (HPV). VGX-3100 utilizes synthetic consensus sequences based on HPV antigens that offer coverage across different viral sub-types (types 16 and 18), which could potentially treat 71% of all cervical cancers.
VGX-3400 is a SynCon DNA-based preventative vaccine targeting avian influenza. In preclinical studies, vaccination with VGX-3400 generated protective levels of hemagglutination inhibition titers in 100% of the immunized animals in five separate animal models – mice, ferrets, rabbits, pigs, and rhesus monkeys.
Joseph Kim, president and CEO of VGX, said: “Using our vertically integrated product development platform, we have taken three independent product programs from ‘Bench to IND filing’ within 12 months. These accomplishments demonstrate the potential and efficiency of our product development platform.”